Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes

Phase 3

Completed

• Conditions: End Stage Kidney Disease; Arteriovenous Fistula; End Stage Renal Disease; ESRD; Chronic Kidney Failure; Vascular Access Complication; Complication of Renal Dialysis; Complication of Hemodialysis
• Interventions: Procedure: AV Fistula Surgery; Drug: Sirolimus; Device: Sirolimus-eluting Collagen Implant (SeCI)

• Registration Number: NCT02513303
• Lead Sponsor: Vascular Therapies, Inc.

Brief Summary

The objective of this study is to evaluate efficacy and safety outcomes following use of the Sirolimus-eluting Collagen Implant (SeCI) in subjects undergoing surgical creation of an AV fistula for vascular access (index procedure).

Detailed Description

The objective of this study is to evaluate efficacy and safety outcomes following use of the Sirolimus-eluting Collagen Implant (SeCI) in subjects undergoing surgical creation of an AV fistula for vascular access (index procedure). Following successful creation of the AV fistula, the cohort randomized to the treatment group will receive the SeCI; the control group will not receive an implant. The primary hypothesis is that the proportion of subjects that meet requirements for fistula suitability for dialysis six months following the index procedure will be higher in the treatment group in comparison to the control group.

Study Timeline

• Study First Submitted: 2015-07-29
• Study First Submitted QC: 2015-07-29
• Study First Posted: 2015-07-31
• Study Start: 2015-11
• Primary Completion: 2021-06
• Study Completion: 2021-06
• Status Verified: 2021-07
• Disposition First Submitted: 2021-07-11
• Disposition First Submitted QC: 2021-07-15
• Disposition First Posted: 2021-07-19
• Last Update Submitted: 2021-07-21
• Last Update Posted: 2021-07-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 269

Inclusion Criteria

• Currently on hemodialysis for ≤12 months or expected to initiate hemodialysis within approximately 6 months of the creation of the AV fistula.
• Vascular anatomy suitable for creation of the AV fistula, determined by pre procedure duplex ultrasound
• Successful creation of a single stage radiocephalic or brachiocephalic end to side fistula

Read More

Exclusion Criteria

• Prior AV access created on the limb where the fistula surgery is planned
• ST-elevation MI or cerebrovascular accident within 30 days of the index procedure
• Known hypersensitivity to the following: sirolimus, beef or bovine collagen
• Hypotension with systolic blood pressures <100 mm Hg at the time of screening
• Known or suspected active infection at the time of the AV fistula surgery
• Known to be HIV positive
• Prisoner, mentally incompetent, and/or alcohol or drug abuser

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control Group	AV Fistula Surgery	AV fistula surgery
Treatment Group	Sirolimus	AV fistula surgery Single administration of sirolimus-eluting Collagen implant
Treatment Group	AV Fistula Surgery	AV fistula surgery Single administration of sirolimus-eluting Collagen implant
Treatment Group	Sirolimus-eluting Collagen Implant (SeCI)	AV fistula surgery Single administration of sirolimus-eluting Collagen implant

Primary Outcome Measures

Name	Time	Method
Fistula Suitability for Dialysis at 6 Months (FSD6)	6 months	For subjects who are on hemodialysis by day 150, suitability for dialysis will be determined by the ability to use the fistula for dialysis using 2-needles with a mean dialysis machine blood pump speed of ≥300 mL/min for two-thirds of the dialysis sessions during a 30 day suitability ascertainment period that begins 150 days after fistula creation.; For subjects who are not on hemodialysis on day of enrollment and who do not initiate hemodialysis by day 150, suitability for dialysis will be determined by a vascular ultrasound performed at the 6 month follow up visit. Suitability for dialysis will be defined as a fistula with an access vein diameter (AVD) of ≥6 mm (internal diameter) and an access blood flow of ≥500 mL/min.

Trial Locations

Locations (4)

Nephrology Consultants, LLC; 🇺🇸 Huntsville, Alabama, United States

AKDHC Medical Research Service; 🇺🇸 Phoenix, Arizona, United States

San Diego Institute of Medical Research; 🇺🇸 Escondido, California, United States

Northeast Clinical Research Center; 🇺🇸 Bethlehem, Pennsylvania, United States